

# Summary of Product Characteristics

## 1 NAME OF THE MEDICINAL PRODUCT

NASONEX 50 micrograms/actuation Nasal Spray, Suspension

## 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Mometasone furoate (as the monohydrate) 50 micrograms/actuation.

### Excipient with known effect

This medicinal product contains benzalkonium chloride.

*For the full list of excipients, see section 6.1.*

## 3 PHARMACEUTICAL FORM

Nasal Spray, Suspension.

*Product imported from Belgium, Greece and Romania*

White to off-white opaque suspension.

## 4 CLINICAL PARTICULARS

As per PA23198/011/001

## 5 PHARMACOLOGICAL PROPERTIES

As per PA23198/011/001

## 6 PHARMACEUTICAL PARTICULARS

### 6.1 List of excipients

*Product imported from Greece:*

dispersible cellulose 65 cps (microcrystalline cellulose and carmellose sodium)

glycerol

sodium citrate

citric acid monohydrate

polysorbate 80

benzalkonium chloride

purified water

*Product imported from Romania:*

Dispersable cellulose (microcrystalline cellulose and sodium carmellose)

Glycerol

Sodium citrate dihydrate

Citric acid monohydrate

Polysorbate 80

Benzalkonium chloride

Purified water

*Product imported from Belgium:*

dispersible cellulose

glycerol

sodium citrate

citric acid monohydrate

polysorbate 80  
benzalkonium chloride  
purified water.

## **6.2 Incompatibilities**

Not applicable.

## **6.3 Shelf life**

The shelf-life expiry date of this product is the date shown on the container and outer carton of the product on the market in the country of origin.

Use within 2 months of first use.

## **6.4 Special precautions for storage**

Do not store above 25°C. Do not freeze.

## **6.5 Nature and contents of container**

NASONEX Nasal Spray is contained in a white, high density polyethylene bottle, that contains 18 g (140 actuations) of product formulation, supplied with a metered-dose, manual polypropylene spray pump actuator.

Pack sizes: 18g: 1 bottle

## **6.6 Special precautions for disposal and other handling**

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

## **7 PARALLEL PRODUCT AUTHORISATION HOLDER**

IMED Healthcare Ltd.  
Unit 625 Kilshane Avenue  
Northwest Business Park  
Ballycoolin  
Dublin 15  
Ireland

## **8 PARALLEL PRODUCT AUTHORISATION NUMBER**

PPA1463/102/001

## **9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 22<sup>nd</sup> of May 2015

## **10 DATE OF REVISION OF THE TEXT**

March 2025